Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022

Rothschedl, E. and Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022. Oncology Fact Sheet Nr. 39.

[thumbnail of Oncology Fact Sheet Nr.39_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
110kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 39
Deposited on:	22 Feb 2021 13:10
Last Modified:	22 Nov 2022 18:06

Repository Staff Only: item control page